GO
Loading...

Elan Corporation PLC

More

  • NEW YORK, Sept 8- Mathew Martoma, a former portfolio manager at billionaire Steven A. Cohen's SAC Capital Advisors LP hedge fund, was sentenced on Monday to nine years in prison for engaging in what authorities called the most lucrative insider trading scheme in U.S. history. District Judge Paul Gardephe in New York also ordered Martoma, 40, to forfeit $9.3 million.

  • NEW YORK, Sept 4- A federal judge on Thursday refused to throw out the insider trading conviction of former SAC Capital portfolio manager Mathew Martoma, saying the trial evidence "overwhelmingly demonstrated Martoma's guilt."

  • NEW YORK, Aug 14- A federal judge rejected billionaire investor Steven A. Cohen's bid to dismiss lawsuits by Elan Corp and Wyeth shareholders who claimed they lost money because his firm SAC Capital Advisors LP conducted insider trading in the drugmakers' stocks.

  • NEW YORK, June 27- Mathew Martoma, a former SAC Capital Advisors portfolio manager convicted of insider trading, should be sentenced to a "substantial" term of prison beyond the eight years recommended by probation officers, U.S. prosecutors argued Friday. In court papers filed in New York federal court, prosecutors urged U.S.

  • SAN DIEGO June 23- Dublin, Ireland- based Alkermes Plc has the low-tax domicile currently in vogue among multinational pharmaceutical companies but is not interested in being bought out as it nears the launch of new drugs, its chief executive said on Monday.

  • NEW YORK, May 28- A prison sentence approaching 20 years would be an appropriate punishment for Mathew Martoma, a former SAC Capital Advisors LP fund manager convicted of insider trading, U.S. court officials said, prompting his lawyers to object strenuously.

  • NEW YORK, May 28- U.S. court officials said Mathew Martoma may deserve a record prison term for insider trading, perhaps approaching 20 years, prompting strenuous opposition from lawyers for the former SAC Capital Advisors LP fund manager.

  • In total, SAC Capital has agreed to pay $1.8 billion to resolve criminal and civil probes into insider trading. SAC Capital also agreed to be placed on probation for five years, and employ a compliance consultant, former federal prosecutor Bart Schwartz.

  • In total, SAC Capital has agreed to pay $1.8 billion to resolve criminal and civil probes into insider trading. SAC Capital also agreed to be placed on probation for five years, and employ a compliance consultant, former federal prosecutor Bart Schwartz. The sentencing marks the end of an era for SAC Capital, which by last year had managed $15 billion of assets.

  • SAC still on hook in insider trading probe: Source Friday, 7 Feb 2014 | 1:03 PM ET
    Mathew Martoma, right, exits federal court with his attorney Roberto Braceras in New York, on Thursday, Feb. 6, 2014.

    The probe into insider trading continues with authorities looking at a number of funds, including SAC Capital, a source tells CNBC.

  • Witness recounts Cohen role in Martoma case Wednesday, 29 Jan 2014 | 8:33 AM ET
    Former hedge fund portfolio manager Mathew Martoma.

    SAC Capital's head trader testified that Steven Cohen had instructed him to start selling Elan stock in accounts that had "less visibility."

  • Witness: I helped Martoma with insider information Friday, 17 Jan 2014 | 3:00 PM ET
    Mathew Martoma (L) walks with wife Rosemary and his lawyer outside Manhattan federal court on Jan. 3, 2013.

    A key witness testified in Matthew Martoma's insider trading scandal that he provided Martoma with confidential information about a drug trial.

  • New catalyst for ol’ Jim Cramer fave? Monday, 16 Dec 2013 | 6:19 PM ET

    Jim Cramer has been a fan of this company for quite some time. But a good stock always needs new catalysts.

  • Ex-SAC trader to cite Cohen testimony in case Saturday, 7 Dec 2013 | 1:43 PM ET

    A former SAC Capital Advisors trader wants to cite in court some 2012 testimony given by the hedge fund's founder Steven Cohen, claiming it rebuts the government's case.

  • Pharma's Holy Grail: The next Alzheimer's drug Thursday, 5 Sep 2013 | 2:30 PM ET
    An Alzheimer's patient

    After two decades of research, a treatment that slows or reverses the progression of Alzheimer's has proved elusive. The aging of the global population makes the need more urgent.

  • Hedge fund holdings: Top managers show their hands Wednesday, 14 Aug 2013 | 12:55 PM ET
    David Einhorn, president and co-founder of Greenlight Capital

    Wednesday marks 45 days since the end of the second quarter, or as it's known in the financial community, "13F Day." Some of the world's biggest funds report their holdings.

  • Big business near critical inflection point? Wednesday, 31 Jul 2013 | 6:53 PM ET

    A new development suggests big companies may be getting fed up with Washington. Really fed up.

  • The wheels keep turning: Pros handicap Fed pick Tuesday, 30 Jul 2013 | 3:15 PM ET
    Janet Yellen and Larry Summers

    Who’s best for the markets, Yellen or Summers? Wall Street debates while awaiting Obama’s pick for the next Fed chairman.

  • 3 mergers Cramer says every investor must know about Monday, 29 Jul 2013 | 6:01 PM ET

    Cramer says a trio of recent deals demands attention.

  • Stocks kicked off the week on a weak note as investors hesitated to jump in ahead of the Federal Reserve meeting and a slew of key economic reports.